Abstract: In the preliminary clinical study of LPAK (Lymphokine and PHA Activated Killer) /IL-2 ( In terleukin-2, IL-2), 17 patients with advanced carcinoma were treated with LPAK/L-2 adoptive immunotherapy, 12 of them were eligible, 2/4 of HCC had 35. 7% and 47. 8% tumor regression respectively. 1 metastatic liver cancer had 39. 5% tumor regression. The tumor regression of the cutaeous T cell lymphoma was more than 50%. We conclude that: LPAK/IL-2 has actual antitumor effects in clinical studies.